C M Financials

Welcome to CM Financials

Professional stock market analysis and investment insights.

NIFTY 50 ▲ 24,350 (+0.82%)     SENSEX ▲ 80,450 (+0.75%)     BANK NIFTY ▲ 53,120 (+1.10%)     RELIANCE ▼ 2,865 (-0.40%)     HDFC BANK ▲ 1,745 (+0.62%)     TCS ▲ 4,120 (+0.55%)
Showing posts with label Stock Watch. Show all posts
Showing posts with label Stock Watch. Show all posts

Friday, 28 February 2025

Markets 28th February

As of February 28, 2025, the Indian stock markets are poised for a cautious opening. The GIFT Nifty, previously known as SGX Nifty, is trading lower by 115 points, or 0.51%, at 22,535.50, indicating a negative start for the day. 

In the previous session on February 27, the Nifty 50 index experienced a flat-to-negative close during the monthly F&O expiry, reflecting a range-bound trend. The index has been on a downward trajectory, falling approximately 14% from its peak in September 2024, and is on the verge of its longest losing streak since 1996. 

Technical analysis suggests that the Nifty 50's support level at 22,500-22,400 is crucial in the near term. Holding above this range may determine the possibility of a rebound, while a breach could signal further declines. Conversely, a bearish gap between 22,670 and 22,720 presents a significant hurdle for any recovery efforts. 

Global cues are also influencing market sentiment. Asian equities have declined, mirroring significant sell-offs on Wall Street, as traders react to underwhelming earnings reports and mixed economic data. Japan's Nikkei share average dropped to a five-month low, with chip-related stocks leading the decline. 

Investors are advised to monitor key economic data releases, including the U.S. GDP figures and initial jobless claims, followed by India's GDP growth numbers. These indicators are expected to provide further direction to the markets in the coming sessions. 

Technical Outlook:

Support Levels: Immediate support is observed at 22,500, with a more substantial base around 22,200. 

Resistance Levels: Key resistance is anticipated between 22,600 and 22,800. 


The formation of a Doji candlestick pattern in the previous session suggests market indecision, indicating potential for a significant move upon breaching these levels. 

Stock-Specific Recommendations for Intraday Trading:

1. Cholamandalam Investment and Finance Company (CHOLAFIN):

Buy Above: ₹1,440

Sell Below: ₹1,425

Rationale: Monitor for a breakout above ₹1,440 for potential upward momentum; conversely, a decline below ₹1,425 may signal further downside. 

2. JSW Steel (JSWSTEEL):

Buy Above: ₹976

Sell Below: ₹968

Rationale: A move above ₹976 could indicate bullish strength, while falling below ₹968 may suggest bearish trends. 

3. State Bank of India Cards (SBICARD):

Buy Above: ₹863

Sell Below: ₹855

Rationale: Trading above ₹863 may present buying opportunities; dropping below ₹855 could warrant caution. 

4. SRF Limited (SRF):

Buy Above: ₹2,850

Sell Below: ₹2,820

Rationale: A breach above ₹2,850 might lead to positive momentum; slipping below ₹2,820 could indicate weakness. 

Market Sentiment:

Global cues reflect caution, with Asian markets trading lower following significant sell-offs on Wall Street. Investors are advised to stay vigilant and consider global economic indicators when making trading decisions. 

*Disclaimer: The above recommendations are based on technical analysis and are for informational purposes only. Traders should conduct their own research and consider their risk tolerance before making investment decisions.*

Thursday, 16 January 2025

Narayana Hrudayalaya Lts

Narayana Hrudayalaya Ltd

ABOUT 

Narayana Hrudalaya Ltd is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations.

KEY POINTS 

Hospital Portfolio
- India: 19 owned/operated hospitals, 2 heart centers, 18 clinics, and dialysis centers.
- Cayman Islands: 1 hospital.
** - Total:** 40 healthcare facilities with 5,789 operational beds (including Cayman).

Multi Speciality Hospital
Cardiac Sciences (32%): Advanced cardiac surgeries, including robotic and pediatric interventions.
Oncology (15%): Comprehensive cancer care with state-of-the-art radiation and surgical technologies.
Medicine & GI Sciences (13%): Treating complex medical and gastrointestinal conditions.
Renal Sciences (10%): Kidney transplants, nephrology, and dialysis.
Neurosciences (8%): Neurology and neurosurgery.
Orthopedics (4%): Joint replacements and robotics.
Others (17%): Pulmonology, pediatrics, and ENT.

PAN India Presence

** East: 7 hospitals, 4 clinics, 1 dialysis center; 1,994 beds.
West: 2 hospitals; 351 beds.
** South: 6 hospitals, 2 heart centers, 12 clinics; 2,006 beds in hospitals, 128 in heart centers.
** North:** 4 hospitals, 1 clinic; 1,200 beds.

Business Mix

Owned Hospitals: 70%.
Operated Hospitals: 27%.
Heart Centers and Ancillary Businesses: 3%.

Payor Mix

Domestic Walk-ins: 45%
Insured Patients: 29%
Government Schemes: 20%
International Patients: 7%

Key Data Points

Average Length of Stay (ALOS): 4.3 days.
Average Revenue Per Patient (ARPP): ₹104k.
Outpatient footfalls: 710k.
ICU Occupied Bed Days: 135k.

International Presence in Cayman Islands

- Revenue: 6.5% of overall revenue
- Discharges: 524.
- Outpatients: 8,819.

The company plans to foray into the Middle East and South-East Asia.

Domestic Revenue Bifurcation
Bangalore: 36%.
Southern Peripheral (Mysore, Shimoga, etc.): 10%.
Kolkata: 26%.
Eastern Peripheral (Jamshedpur, Guwahati, etc.): 9%.
Northern: 14%.
Western: 8%.

Venture into IT Sector
It incorporated a WoS named "MEDHA AI PVT LTD" on Dec,23, to conduct business in various IT services, encompassing software development, solutions, design, testing, and more.

FY24 CAPEX
Co. incurred 382 Crs of capex spent on replacement, maintenance, and expansion.

FY25 Projected CAPEX
a) Greenfield and inorganic growth: 221 Crs
b) Facility transformation and medical equipment upgrades: 218 Crs
Major Investments:
- NICU, PICU, orthopedic robotics, and single rooms.
- New clinics and land for expansion
The Scrip traded around on Thursday 16 Jan 2025 ₹1309

Overall:
NHL seems well-positioned for long-term growth, thanks to its strong brand, focus on affordability, and the expanding healthcare market in India.
It's good buy for Long-term.